二氧化物纳米颗粒缓解生物化学和分子变化 标志着老鼠阿尔茨海默氏病的特征
Sara A Abdel Gaber1, Amal H Hamza2, Mohamed A Tantawy3,4
1Nanomedicine Department, Institute of Nanoscience and Nanotechnology, Kafrelsheikh University, Kafr El Sheikh 33516, Egypt.
Pharmaceutics
|May 27, 2023
概括
在临床前模型中,二氧化纳米粒子 (GeO2NP) 通过减少关键生物标志物和改善大脑健康来治疗阿尔茨海默病 (AD) 是有前途的. 这项研究强调了GeO2NP作为AD的潜在治疗剂.
科学领域:
- 神经科学是一个神经科学.
- 材料科学 材料科学 材料科学
- 生物化学 生物化学
背景情况:
- 阿尔茨海默病 (AD) 是一种进展性神经退行性疾病,有效治疗方法有限.
- 基于纳米粒子的疗法正在成为神经退行性疾病的潜在策略.
研究的目的:
- 评估二氧化纳米颗粒 (GeO2NP) 在减轻阿尔茨海默病 (AD) 的有效性.
- 在AD大鼠模型中,将GeO2NP与二氧化纳米粒子 (CeO2NP) 的治疗潜力进行比较.
主要方法:
- GeO2NP和CeO2NP被合成并以抗氧化活性为特征.
- 鼠被分为四组:对照组,AD组,AD+GeO2NPs组和AD+CeO2NPs组.
- 分析了生物化学标记物 (,粉样β,ACHE,MAO),大脑组织病理学和AD相关的微RNA.
主要成果:
- 与CeO2NP相比,GeO2NP显示出更高的抗氧化活性.
- 用GeO2NP治疗显著降低了血清和脑组织中的AD生物标志物,接近对照水平.
- 组织病理学发现证实了生物化学结果,表明GeO2NPs的神经保护作用.
结论:
- 地质O2NP显示出管理阿尔茨海默病的巨大潜力,提供了一条新的治疗途径.
- 这项研究提供了第一个证据,证明了GeO2NP在体内AD模型中的有效性.
- 需要进一步的研究来阐明在AD治疗中GeO2NP的精确作用机制.
相关概念视频
Alzheimer's Disease: Treatment
226
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
226
Alzheimer's Disease: Overview
539
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
539


